The stock of Sana Biotechnology Inc (NASDAQ: SANA) has increased by 8.63 when compared to last closing price of 2.52. Despite this, the company has experienced a -5.93% fall in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-09 that Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes
Is It Worth Investing in Sana Biotechnology Inc (NASDAQ: SANA) Right Now?
SANA has 36-month beta value of 1.80. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for SANA is 125.44M, and currently, short sellers hold a 35.28% ratio of that float. The average trading volume of SANA on June 17, 2025 was 3.83M shares.
SANA’s Market Performance
The stock of Sana Biotechnology Inc (SANA) has seen a -5.93% decrease in the past week, with a 56.88% rise in the past month, and a 20.07% gain in the past quarter. The volatility ratio for the week is 4.20%, and the volatility levels for the past 30 days are at 7.21% for SANA. The simple moving average for the past 20 days is 14.52% for SANA’s stock, with a -3.66% simple moving average for the past 200 days.
Analysts’ Opinion of SANA
Many brokerage firms have already submitted their reports for SANA stocks, with Citizens JMP repeating the rating for SANA by listing it as a “Mkt Outperform.” The predicted price for SANA in the upcoming period, according to Citizens JMP is $5 based on the research report published on March 18, 2025 of the current year 2025.
Jefferies, on the other hand, stated in their research note that they expect to see SANA reach a price target of $7. The rating they have provided for SANA stocks is “Buy” according to the report published on March 14th, 2025.
SANA Trading at 37.41% from the 50-Day Moving Average
After a stumble in the market that brought SANA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.01% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SANA starting from CHRISTIAN HORDO & KATHARINE HO, who proposed sale 75,000 shares at the price of $3.16 back on Feb 18 ’25. After this action, CHRISTIAN HORDO & KATHARINE HO now owns shares of Sana Biotechnology Inc, valued at $237,000 using the latest closing price.
CHRISTIAN HORDO & KATHARINE HO, the Officer of Sana Biotechnology Inc, proposed sale 75,000 shares at $3.86 during a trade that took place back on Jan 16 ’25, which means that CHRISTIAN HORDO & KATHARINE HO is holding shares at $289,500 based on the most recent closing price.
Stock Fundamentals for SANA
The total capital return value is set at -0.52. Equity return is now at value -71.44, with -37.04 for asset returns.
Based on Sana Biotechnology Inc (SANA), the company’s capital structure generated 0.3 points at debt to capital in total, while cash flow to debt ratio is standing at -2.26.
Currently, EBITDA for the company is -251.27 million with net debt to EBITDA at 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.40.
Conclusion
To put it simply, Sana Biotechnology Inc (SANA) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
